Berkowits Scales Hair and Skin Clinic Franchises Across India

By Amara Osei

Berkowits Hair and Skin Clinics says it operates 45 clinics across more than 17 cities and is expanding through two franchise formats: Standard and Luxe.

CEO Arpit Goel said the business began moving beyond Delhi NCR as demand grew in other markets. The network now covers Delhi NCR, Mumbai, Bengaluru, Hyderabad, Pune, Kolkata and several Tier 2 cities. Berkowits also acquired Richfeel Hair Clinics in 2024, adding to its national presence and product portfolio.

What does Berkowits offer?

The clinical menu covers:

• Surgical hair transplants and non-surgical hair replacement.
• Hair-loss treatments and laser hair reduction.
• Skin treatments and anti-ageing procedures.

The company also sells more than 100 own-brand SKUs under Grow, Nourish, Renew, Radiate, Protect and Clear. This puts consultations, clinical procedures and an in-house hair and skin-care range under one brand.

The proposition combines treatment delivery with product sales.

How do the AI tools shape consultations?

An AI-powered hair generator lets clients preview different hairstyles before choosing a non-surgical hair-replacement solution. A second tool, an AI-enabled digital microscope or trichoscope, assesses scalp health and tracks changes in hair density and thickness.

Berkowits says the system gives consultants a clearer way to explain treatment progress and communicate results with clients. The hair generator handles visual decision-making; the trichoscope supplies a measurable view of scalp and density changes.

The technology makes the consultation more visual without replacing clinical judgement.

How do Standard and Luxe clinics differ?

A Luxe clinic includes an operation theatre for hair-transplant procedures. The Standard format functions as a local treatment and booking centre, referring transplant work to a nearby Luxe clinic.

That structure gives the brand two routes for building a local presence. It can establish treatment and consultation access through Standard sites while concentrating surgical facilities within the wider Luxe network.

Standard clinics build reach; Luxe clinics house the surgical procedure.

What do the franchise models require?

Berkowits is presenting two operating structures with different levels of partner involvement:

• FOCO: The franchise partner invests, while Berkowits manages the clinic’s operations.
• FO: The partner takes a more active role in local management, backed by the brand’s training, marketing, HR and operational teams.

The commercial terms differ as well. Berkowits’s presentation lists a 15% revenue share under its FOCO proposal and a 10% royalty under its FO proposal. These belong to separate operating models, so the percentages should not be treated as directly comparable headline rates. No upfront investment figure accompanies them in the announcement.

The presentation also contains projected returns and payback periods, but Berkowits treats those figures as estimates rather than guaranteed outcomes. Prospective franchisees need to confirm the applicable investment, revenue-sharing and royalty terms directly with the company.

The headline percentages matter less than the capital requirement and operating responsibility behind them.

Who is Berkowits seeking?

The company is particularly interested in FO partners in Tier 2 and Tier 3 markets, where it sees a role for local management in overseeing day-to-day operations. A medical background is not necessarily required because training is provided. Clinical procedures, however, must be performed by appropriately qualified professionals in line with applicable requirements.

Berkowits plans to grow beyond its existing company-operated network through partners, including clustered clinic networks in markets where it sees scope for a stronger local presence. Site selection will depend on location suitability, investment capacity, local demand and the commercial terms agreed with the brand.

The next stage will test whether partner-led clinics can expand Tier 2 and Tier 3 coverage without diluting clinical standards.